Carter Keller
Senior Vice President at Grifols and head of GigaGen.
Articles
GigaGen's New Contract with BARDA for Polyclonal Antibody Development
October 4th 2024Carter Keller discusses the company's recent $135.2 million contract with BARDA to develop recombinant polyclonal antibody therapies targeting botulinum neurotoxins and an unspecified biothreat, highlighting their innovative approach to address emerging health threats.
Read More
Latest Updated Articles
Published: August 27th 2024 | Updated: August 28th 2024
Concerns Over Mosquito-Borne Illness Causes Massachusetts Town to Create Curfew for Parks, Spraying in Counties
Published: November 12th 2024 | Updated: November 14th 2024
Rebuilding Trust in Intranasal Vaccines for Avian Flu and Other Respiratory Diseases
Published: November 11th 2024 | Updated: November 14th 2024
Clinical Considerations for Treating Patients with Pneumonia
Published: April 1st 2024 | Updated: November 14th 2024
Mixed Fungal Brain Abscess
Published: April 3rd 2024 | Updated: November 14th 2024
Soil to Lungs: The Expanding Threat of Valley Fever
Published: April 4th 2024 | Updated: November 14th 2024
Enhancing Diagnosis and Awareness of Fungal Diseases
